Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I updated this site for more information.
I agree, I am learning, can't believe all articles. I will check more information for I do. Auspex's articles is still on MarketWatch. I wish they can take if off too.
Looking really good for MANF!
All the bad news about WSTI from Auspex Research. I do not believe him anymore. It is all lies.
SolarMill system look nice on the building.
Only $999.00 and take 2 colours: http://cubify.com/en/Cube
A least $70 is not as bad as $10,000. You are lucky that you only put a small amount.
I always check the financials at http://www.marketwatch.com/ click on Watchlist then add HIMRD. If they do not, don't buy. They should have financials and HIMRD does not.
Going down way too fast! That how scam work!
You also lost a lot of money because of HIMRD. This is terrible.
Yes I agree! No financial and liquidity. I would not buy stocks that do not have financial information. Also the printers cost too high.
Hopefully they will improve!
Check the Public Company Comparables at the bottom of the website:
http://www.tinkerine.com/investor/TS_Corporate_Fact_Sheet_0829.pdf
Doesn't look good.
Sound good! Way to go AMBS!
Alzheimer's Disease Clinical Trials: Dr. Laurie Ryan
Caution If you've been asked to invest in a company but you can't find any record that the company has registered its securities with the SEC or your state, or that it's exempt from registration, call or write your state's securities regulator or submit a complaint to the SEC at http://www.sec.gov/complaint/select.shtml immediately with all the details. You may have come face-to-face with a scam.
That is a good question, I do not know why. Maybe it is too hard find them. There are some did got caught and got in trouble.
The trouble is that they could be in another country, fake names and etc. Cost a lot money for lawyer. It would be good if you can find them.
#C4CT Wrap-up and the Decision to Present Interim LP-002 Data - See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/c4ct-wrap-decision-present-interim-lp-002-data/#MDM
Immediately following Dr. Arendt’s presentation, Dr. Louis Kirby shared some positive top-line interim data from the Company’s ongoing LP-002 clinical study for LymPro where we demonstrated that with a single marker, CD19, we were able to distinguish Alzheimer’s disease from healthy controls in a population of 44 subjects. The Company had been planning on sharing top-line data from the full 72 subject study, and was disappointed this was not possible at #C4CT. When the Company became aware that 3 of the 4 sites had not completed their full enrollment, in part due to stringency in the Alzheimer’s subject selection criteria, we also became aware that one of the sites had exceeded its enrollment criteria as it was able to get through Institutional Review Board (IRB) approval well ahead of the other sites. We decided to un-blind the single site and perform an interim analysis for the purpose of being able to keep our previously outlined timeline on LymPro commercialization, and because #C4CT was a unique opportunity to recruit collaborators for the LymPro project. We will continue to focus our efforts on extracting the best univariate markers from LymPro through the completion of the LP-002 bridging study ahead of endeavoring to establish the multivariate predictive modeling that will become the basis of the ultimate clinical diagnostic that will be used commercially. - See more at: http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/c4ct-wrap-decision-present-interim-lp-002-data/#MDM
http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/c4ct-wrap-decision-present-interim-lp-002-data/#MDM
Sound good! It would nice a lot of school will be interested.
All lies!
Amarantus Shareholders Approve All Matters Voted Upon at Annual Shareholders Meeting
http://www.marketwatch.com/story/amarantus-shareholders-approve-all-matters-voted-upon-at-annual-shareholders-meeting-2014-09-25
Yes, I am with GC 100%! All the good news and letting us know what is going on. What they are doing is amazing!
Then he is making it up!
That means that HIMRD is keeping the profit! Another word Scam!
Negative EPS
Companies don't always turn a profit. Sometimes they lose money, in which case their earnings are negative. When earnings are negative, then EPS will be negative, too. A negative EPS tells you exactly how much money the company lost per share of outstanding stock, which is why you'll also see it called "net loss per share." If a company with 100 million shares loses $16 million, then its EPS is negative 16 cents. No, the company isn't going to send someone to shake you down for 16 cents per share. But you'll still "pay" for the loss in another way: A net loss decreases the value of the firm, which typically lowers the value of the stock.
Dr. David Lowe, PhD – Independent Director
Yes, thanks, Gerald. Good afternoon, everyone. Well, as you heard, I recently joined
the Amarantus Board, and will be leading the R&D effort on the MANF program. Just
to say that I’ve been following the scientific literature on MANF for some time, and
was really excited to take on this role when approached by Gerald and the board to
join the team.
The main reason for my excitement is that MANF truly represents breakthrough
biology; is involved in protecting stress cells from toxic effects and death.
Furthermore, the company has a strong patent position; so it’s very fundamental
mechanism with a huge commercial upside and exactly what I was looking for.
Going forward, for now, our task is to bring MANF to clinical trials as soon as possible,
demonstrate this potential to improve patient’s lives, and thereby increase shareholder
value. Alongside the data we’ve produced in the past in Parkinson’s disease, there
are now studies showing positive effects of MANF in a number of orphan indications.
Orphan diseases are interesting because they have lower regulatory hurdles, smaller
trials with less expensive development costs, produce excellent returns, and are in the
suite of … for partnering.
Human clinical proof of concepts, anti-cell death in particular, would massively
increase the value of MANF in our view. Concurrently, we are looking at into
appropriate orphan diseases. In this context, we were very happy to announce
positive data for MANF in the degenerative disease known as Retinitis Pigmentosa, or
RP as I’ll now refer to it.
The study concluded that intravitreal injection of recombinant human MANF protein
protects both rods and cones from retinal degeneration in an animal model of RP. RP
is a degenerative disorder of the eyes that affects roughly 100,000 people in the U.S.,
meaning that it qualifies as an orphan disease under FDA guidelines.
RP refers to a group of inherited diseases causing retinal degeneration, and most
people with RP are legally blind by age 40. It is estimated that the market opportunity
for RP exceeds ten billion dollars annually; so we could now expand the MANF
therapeutic development franchise into ophthalmology. We’ll also explore other
indications in that therapeutic area.
By identifying RP as an indication for MANF, we’ve identified a potentially reduced
timeline to get MANF to commercialization with a very substantial market opportunity.
Exactly what I was referring to in my opening comments.
We will seek to partner with biopharmaceutical companies in order to create and
accelerate our development program, and assist in recruiting patients for further
clinical studies at the appropriate stage. This does not mean, however, we are
abandoning MANF Parkinson’s disease; in fact, far from it. We will continue
developing the MANF Parkinson’s program, and have a number of studies in the
planning stage.
Producing neuroprotective data in RP will, in fact, support the PD program from both a
scientific, development, and commercial perspective.
With that now, I’ll turn the call back to Gerald. Gerald?
Reverse splits in the pennies don't work the way you think:
http://www.rapidstockprofits.net/showthread.php?t=32
No way they will let you know if they did have a business. They can get in big trouble with the law if they're caught.
Yes that is odd, too coincidence. Also both have Mail Box too.
Hard to know for sure.
Phone # of those business:
Pizza Hut 1-417-239-1111
CherryBerry 1-417-544-9069
Mail Box Phone: 1-417-336-4405 Fax: 1-417-336-4406
Branson Cigar: 1-417-332-8080
I hope you good luck!
Yes, now I see their new business address on google maps. At that address there are: Pizza Hut, CherryBerry, Mail Box and Branson Cigar.
I think he bought shares again. He is with AMBS now.
I hope you will get your $10,000 back. Sadly to say, not will HIMRD. Good Luck!
I can't see 3000 Green Mountain Drive, Branson, MO 65616, United States
on Google Maps
But there is| 2999 Green Mountain Drive and next 3001 Green Mountain Drive
Sound good! That would be good if they will get a partnership soon.
Sorry, check this URL for Tinkerine's Printers: http://www.tinkerine.com/store/3d-printers/